← FDA DRUG APPROVALS

FDA ANDA · ANDA062338

ERYC

Sponsor: WARNER CHILCOTT LLC

APPLICATION
ANDA062338
TYPE
ANDA
ORIGINAL APPROVAL
1981-05-22
LATEST ACTION
2000-12-21
ROUTE
ORAL
DOSAGE FORM
CAPSULE, DELAYED REL PELLETS
MARKETING STATUS
Discontinued

Products

ERYCDiscontinued
ERYTHROMYCIN 250MG · CAPSULE, DELAYED REL PELLETS · ORAL

Approval history

2000-12-21Manufacturing (CMC) · Supplement 11AP
2000-09-12Manufacturing (CMC) · Supplement 10AP
1998-02-06Manufacturing (CMC) · Supplement 9AP
1997-07-31Manufacturing (CMC) · Supplement 8AP
1991-05-17Labeling · Supplement 5AP
1981-05-22OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →